Logo image of RVNC

REVANCE THERAPEUTICS INC (RVNC) Stock Fundamental Analysis

USA - NASDAQ:RVNC - US7613301099 - Common Stock

3.65 USD
+0.01 (+0.27%)
Last: 2/5/2025, 8:25:21 PM
3.66 USD
+0.01 (+0.27%)
After Hours: 2/5/2025, 8:25:21 PM
Fundamental Rating

2

Overall RVNC gets a fundamental rating of 2 out of 10. We evaluated RVNC against 195 industry peers in the Pharmaceuticals industry. RVNC has a bad profitability rating. Also its financial health evaluation is rather negative. RVNC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RVNC has reported negative net income.
RVNC had a negative operating cash flow in the past year.
In the past 5 years RVNC always reported negative net income.
In the past 5 years RVNC always reported negative operating cash flow.
RVNC Yearly Net Income VS EBIT VS OCF VS FCFRVNC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

RVNC has a Return On Assets of -39.96%. This is comparable to the rest of the industry: RVNC outperforms 44.62% of its industry peers.
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROIC N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RVNC Yearly ROA, ROE, ROICRVNC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

RVNC has a Gross Margin of 72.61%. This is in the better half of the industry: RVNC outperforms 79.57% of its industry peers.
In the last couple of years the Gross Margin of RVNC has remained more or less at the same level.
RVNC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
RVNC Yearly Profit, Operating, Gross MarginsRVNC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

2

2. Health

2.1 Basic Checks

RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RVNC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RVNC has been increased compared to 5 years ago.
RVNC has a worse debt/assets ratio than last year.
RVNC Yearly Shares OutstandingRVNC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RVNC Yearly Total Debt VS Total AssetsRVNC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.34, we must say that RVNC is in the distress zone and has some risk of bankruptcy.
RVNC's Altman-Z score of -6.34 is on the low side compared to the rest of the industry. RVNC is outperformed by 67.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.34
ROIC/WACCN/A
WACC8.5%
RVNC Yearly LT Debt VS Equity VS FCFRVNC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.12 indicates that RVNC has no problem at all paying its short term obligations.
RVNC's Current ratio of 4.12 is in line compared to the rest of the industry. RVNC outperforms 59.14% of its industry peers.
RVNC has a Quick Ratio of 3.05. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
RVNC has a Quick ratio (3.05) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.05
RVNC Yearly Current Assets VS Current LiabilitesRVNC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.16% over the past year.
Looking at the last year, RVNC shows a quite strong growth in Revenue. The Revenue has grown by 15.34% in the last year.
RVNC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.20% yearly.
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%

3.2 Future

RVNC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.17% yearly.
RVNC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.31% yearly.
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RVNC Yearly Revenue VS EstimatesRVNC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
RVNC Yearly EPS VS EstimatesRVNC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVNC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVNC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVNC Price Earnings VS Forward Price EarningsRVNC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVNC Per share dataRVNC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RVNC's earnings are expected to grow with 22.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.61%
EPS Next 3Y22.8%

More info and screens

0

5. Dividend

5.1 Amount

RVNC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (2/5/2025, 8:25:21 PM)

After market: 3.66 +0.01 (+0.27%)

3.65

+0.01 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners72.87%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change0%
Market Cap381.02M
Analysts70.67
Price Target5.25 (43.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)4.62%
Max EPS beat(2)33.41%
EPS beat(4)4
Avg EPS beat(4)19.57%
Min EPS beat(4)4.62%
Max EPS beat(4)33.41%
EPS beat(8)5
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-3.54%
EPS beat(16)10
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-8.84%
Min Revenue beat(2)-14.73%
Max Revenue beat(2)-2.96%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-14.73%
Max Revenue beat(4)10.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.2%
Revenue beat(12)6
Avg Revenue beat(12)-0.84%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-31.93%
PT rev (3m)-42.51%
EPS NQ rev (1m)-18.27%
EPS NQ rev (3m)-57.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.24%
Revenue NQ rev (1m)6.51%
Revenue NQ rev (3m)-13.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.37
BVpS-1.56
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.61%
FCFM N/A
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.69%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.05
Altman-Z -6.34
F-Score3
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)54.97%
Cap/Sales(3y)6.23%
Cap/Sales(5y)171.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%
EBIT growth 1Y31.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.87%
EBIT Next 3Y26.12%
EBIT Next 5Y20.68%
FCF growth 1Y9.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.22%
OCF growth 3YN/A
OCF growth 5YN/A